EVT.F - Evotec SE

Frankfurt - Frankfurt Delayed Price. Currency in EUR
23.87
-0.29 (-1.20%)
As of 6:24PM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close24.16
Open24.11
Bid23.74 x 400000
Ask23.83 x 400000
Day's Range23.67 - 24.24
52 Week Range14.36 - 25.75
Volume1,313
Avg. Volume9,632
Market Cap3.617B
Beta (3Y Monthly)0.68
PE Ratio (TTM)38.01
EPS (TTM)0.63
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.58
  • ACCESSWIRE13 hours ago

    Evotec Se Places First Schuldschein (Promissory Note) Worth Eur 250 M

    PROCEEDS TO BE USED FOR GENERAL CORPORATE FINANCING INCLUDING FINANCING OF JUST.BIO ACQUISITION, EXPANSION, AND REFINANCING STRONG PERFORMANCE AND OUTLOOK OF THE COMPANY APPEALS TO DEBT INVESTORS AND RESULTS ...

  • ACCESSWIRE2 days ago

    Evotec, Sensyne Health, The University Of Oxford, OSI, and OUI Create New Bridge Partnership 'LAB10X' In Digital Health

    HAMBURG, GERMANY, and OXFORD, UK / ACCESSWIRE / June 24, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that it has entered into a new strategic partnership with the British clinical AI technology company Sensyne Health plc (SENS) ("Sensyne"), the University of Oxford, Oxford University Innovation Ltd ("OUI", the university's research commercialisation company), and Oxford Sciences Innovation ("OSI", the world's largest IP investment company dedicated to a single university) to fund a new BRIDGE called LAB10x. This BRIDGE is aimed at accelerating the translation of research in the fields of clinical artificial intelligence and digital health at Oxford into forming new companies applying breakthrough digital solutions, clinical AI algorithms and accelerated data-driven drug discovery and development.

  • ACCESSWIRE7 days ago

    Resolutions of the Annual General Meeting 2019 of Evotec SE

    HAMBURG, GERMANY / ACCESSWIRE / June 19, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that its shareholders approved all proposals the Company's Management put to vote at the Company's Annual General Meeting 2019 with very strong supporting majorities. The Management Board presented the Company's progress in the year 2018 and provided the shareholders with an update and outlook regarding future developments of the Company in their presentation "ExcellenceSQUARED". The strategy and its execution by the members of the Management Board and the Supervisory Board for the fiscal year 2018 were supported and approved.

  • ACCESSWIRE16 days ago

    Evotec Receives $ 23.8 M Grant To Join The Global Fight Against Tuberculosis

    HAMBURG, GERMANY / ACCESSWIRE / June 10, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the company has entered into a five-year partnership with the Bill & Melinda Gates Foundation to discover new treatment regimens that better address tuberculosis ("TB"), a severe global health burden and one of the leading causes of death due to infectious diseases worldwide. The current standard treatment regimen for TB consists of a minimum of 6 months of treatment with 4 drugs administered under direct observation, but treatment is much longer when TB is drug resistant.

  • ACCESSWIRE21 days ago

    Evotec And Celgene Further Expand Ipsc Collaboration Including New Cell Type

    HAMBURG, GERMANY / ACCESSWIRE / June 5, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its strategic alliance with Celgene Corporation ("Celgene") has been expanded to include a new cell type triggering a payment of $ 9.0 m to Evotec. Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases.

  • ACCESSWIRElast month

    Evotec SE to Acquire Just Biotherapeutics, Inc.

    HAMBURG, GERMANY / ACCESSWIRE / May 20, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) announced today the signing of a definitive agreement under which Evotec ...

  • ACCESSWIRElast month

    Evotec Jump-Starts Biologics with Acquisition of Just Biotherapeutics

    EVOTEC'S OFFERING OF INTEGRATED SOLUTIONS EXTENDED TO BIOLOGICS ADDITION OF LONGSTANDING BIOLOGICS EXPERTISE BASED ON KEY TALENTS, INNOVATIVE ML (MACHINE LEARNING) DRIVEN TECHNOLOGIES AND SOPHISTICATED ...

  • ACCESSWIRElast month

    Evotec To Attend Upcoming Investor Conferences

    HAMBURG, GERMANY / ACCESSWIRE / May 15, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at and attending the following ...

  • ACCESSWIRElast month

    Evotec SE Reports First Quarter 2019 Results And Provides Corporate Update

    - VERY GOOD START WITH 27% INCREASE IN GROUP REVENUES AND STRONG UNDERLYING INDICATIONS FOR FY 2019 - GOOD PROGRESS IN EXISTING CO-OWNED PORTFOLIO AND EXPANDING WITH NEW ALLIANCES - WEBCAST AND CONFERENCE ...

  • ACCESSWIRE2 months ago

    Evotec SE to Report First Quarter 2019 Results on 14 May 2019

    HAMBURG, GERMANY / ACCESSWIRE / May 7, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) will report its financial results for the first quarter of 2019 on Tuesday, 14 May ...

  • ACCESSWIRE2 months ago

    Evotec Completes Repayment Of EUR 140 M Acquisition Loan

    EUR 140 M BRIDGE LOAN WAS DRAWN TO SECURE EVOTEC'S VALUE CHAIN EXPANSION BY SUCCESSFUL ACQUISITION OF APTUIT IN AUGUST 2017 STRONG OPERATIONAL CASH FLOW ENABLES FULL REPAYMENT WITHIN LESS THAN TWO YEARS ...

  • ACCESSWIRE2 months ago

    Evotec And Indivumed Announce Strategic Drug Discovery Collaboration On Precision Medicine For Colorectal Cancer

    HAMBURG, GERMANY / ACCESSWIRE / April 11, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Indivumed GmbH announced today that they have entered into a research collaboration to discover and develop first-in-class therapeutics for the treatment of colorectal cancer ("CRC"). The collaboration, which runs for an initial term of two years, will combine Evotec's proprietary bioinformatics analysis platform "PanHunter" as well as its small molecule and antibody discovery platforms with the CRC cohort of Indivumed's true multi-omics cancer database "IndivuType".

  • ACCESSWIRE3 months ago

    EVOTEC AG COMPLETES CONVERSION INTO EVOTEC SE

    HAMBURG, GERMANY / ACCESSWIRE / April 1, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that it has completed its conversion into a company under European ...

  • ACCESSWIRE3 months ago

    EVOTEC AG FISCAL YEAR 2018 RESULTS: ACCELERATED GROWTH AND STRONG LONG-TERM OUTLOOK

    - EXCELLENCE IN SCIENCE, PARTNERED DRUG DISCOVERY & DEVELOPMENT, ACQUISITIONS, AND UNIQUE PLATFORM TECHNOLOGIES LEAD TO STRONG GROWTH MOMENTUM - STRONG FINANCIAL RESULTS: 42% INCREASE IN GROUP REVENUES, ...

  • ACCESSWIRE3 months ago

    Evotec And The Mark Foundation For Cancer Research Announce Strategic Collaboration In Immuno-Oncology

    HAMBURG, GERMANY / ACCESSWIRE / March 26, 2019 / Evotec AG (EVT.DE), (MDAX/TecDAX, ISIN: DE0005664809) and The Mark Foundation for Cancer Research today announced that they have entered into a research collaboration to discover and develop first-in-class therapeutics in oncology. The collaboration, for an initial period of two years, is based on Evotec's new proprietary drug discovery platform TargetAlloMod, which is focused on disrupting cell signalling via a novel mechanism of action. The Mark Foundation's focus of funding highly innovative oncology research and drug discovery is extremely well aligned with Evotec's mission to exploit novel platforms for the generation of first-in-class and clearly differentiated therapies.

  • ACCESSWIRE3 months ago

    Evotec AG to Report Fiscal Year 2018 Results on 28 March 2019

    HAMBURG, GERMANY / ACCESSWIRE / March 21, 2019 / Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) will report its financial results for 2018 on Thursday, 28 March 2019. The Company ...

  • ACCESSWIRE3 months ago

    Evotec And GARDP Announce New Partnership To Discover Novel Antibiotics

    COLLABORATION EXPLORES OPPORTUNITIES TO SET UP ANTIBIOTIC DISCOVERY AND DEVELOPMENT PLATFORM AND ESTABLISH A JOINT PIPELINE OF NOVEL ANTIBIOTIC ASSETS DISCOVERY EFFORTS WILL FOCUS ON WORLD HEALTH ORGANIZATION ...

  • ACCESSWIRE4 months ago

    Evotec to Attend Upcoming Investor Conferences

    HAMBURG, GERMANY / ACCESSWIRE / March 7, 2019 / Evotec AG (FSE: EVT, OTC PINK: EVTCY, MDAX/TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at and attending the following ...

  • Benzinga5 months ago

    The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 6) Array Biopharma Inc (NASDAQ: ARRY ) Millendo Therapeutics ...

  • ACCESSWIRE5 months ago

    Evotec And Galapagos Enter Into Collaboration In The Field Of Fibrosis

    COLLABORATION COMPRISES LICENCE AGREEMENT FOR A PROGRAMME DEVELOPED BY EVOTEC AS WELL AS ITS DRUG DISCOVERY CAPABILITIES EVOTEC RECEIVES UNDISCLOSED UPFRONT PAYMENT AND IS ELIGIBLE FOR POTENTIAL MILESTONES ...

  • ACCESSWIRE5 months ago

    Evotec Receives Milestone Payment for Start of Phase II Clinical Trial

    EVOTEC'S PARTNER, SECOND GENOME, BEGINS A PHASE II CLINICAL TRIAL FOR NASH WITH LICENSED MOLECULE, SGM-1019 HAMBURG, GERMANY / ACCESSWIRE / January 24, 2019 / Evotec AG (Frankfurt Stock Exchange: EVT, ...

  • ACCESSWIRE6 months ago

    Evotec Reaches Important Scientific Achievement Within IPSC-Based Collaboration With Celgene

    HAMBURG, GERMANY / ACCESSWIRE / January 8, 2019 / Evotec AG (EVT.DE) (EVT.DE) (OTC PINK: EVTCY), (MDAX/TecDAX, ISIN: DE0005664809) announced today that its strategic alliance with Celgene Corporation ("Celgene") has reached another important scientific achievement, resulting in Celgene designating a programme and triggering a payment of $ 14.0 m to Evotec. This scientific achievement was the advancement of a programme into the lead optimisation stage developed from Evotec's compound library using its induced pluripotent stem cell ("iPSC")-based screening platform.

  • ACCESSWIRE6 months ago

    Evotec Invests in Financing Round Of Exscientia

    $ 26 M FINANCING ROUND (SERIES B) INCLUDES CELGENE, GT HEALTHCARE CAPITAL PARTNERS AND EVOTEC PROCEEDS TO ACCELERATE SCALING AS LEADING AI DRUG DISCOVERY COMPANY HAMBURG, GERMANY / ACCESSWIRE / January ...

  • ACCESSWIRE6 months ago

    Evotec AG increases its profitability guidance for 2018

    HAMBURG, GERMANY / ACCESSWIRE / December 19, 2018 / Evotec AG (FSE: EVT), (XETRA: EVT) (MDAX/TecDAX, ISIN: DE0005664809) today announced that it increases its profitability guidance for the current year ...